Biologic Drug Substance And Drug Product Preferred Provider Use

In Q4, 2018 ISR asked 124 outsourcers of biologic drug substance and 138 outsourcers of biologic drug product about their organizations’ use of preferred providers. The data show the majority of respondents from both categories work at companies that use a preferred provider approach to outsourcing, and average about four CMOs on their lists.